About this webinar
A number of solubility enhancing technologies are available to formulators to improve the bioavailability of poorly water-soluble molecules. The choice of a bioavailability enhancing technology can be rationally based on an understanding of the physical-chemical properties of the molecule augmented with in-vitro measurements to help define the mechanism that is limiting bioavailability. For example, the bioavailability of molecules with poor dissolution rates can be improved with straightforward solutions such as particle size reduction. Conversely, molecules that are poorly soluble due to high crystal forces or high lipophilicity can be improved by the use of amorphous solid dispersions (ASD) or lipid-based formulations (LBF), respectively. Commercial products have been developed using each of these technologies.
This presentation will discuss the fundamental formulation and processing considerations for obtaining a high-performing and physically- and chemically stable formulation without excessive formulation or process iteration. In addition, in vitro methodologies for choosing the most appropriate technology based on compound properties will be presented. For each of these formulation case studies, validation of the technology selection methods will be confirmed with animal in-vivo data.
- Describe bioavailability enhancing (BAE) technologies
- Identify In vitro methodologies for choosing BAE technologies
- Discuss technology selection case studies
- Examine In vivo validation of methodologies